市場調查報告書
商品編碼
1532134
胎兒監護市場:依產品、攜帶性、方法、應用、最終用戶、地區、機會、預測,2017-2031Fetal Monitoring Market Assessment, By Product, By Portability, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
2024-2031年預測期間,全球胎兒監護市場規模預計將以7.02%的年複合成長率擴大,從2023年的45.4億美元成長到2031年的78.1億美元。出生率上升、妊娠相關併發症的流行以及技術進步等因素推動全球胎兒監測市場的發展。
胎兒監視器是用於評估懷孕期間胎兒健康狀況的重要工具。這些設備包括超音波系統、電子胎兒監視器和胎兒多普勒儀,可幫助醫療保健提供者監測胎兒心率、胎動和母體宮縮。這一成長是由多種因素推動的,包括早產和妊娠相關併發症發生率上升、技術進步以及孕產婦護理意識的提高。然而,高成本、監管障礙以及準媽媽和醫療保健提供者意識有限等挑戰可能會阻礙市場擴張。雖然北美目前佔據最大的市場佔有率,但在醫療保健基礎設施改善和對先進監控解決方案的需求不斷成長的推動下,亞太地區預計將呈現最高的成長率。
2024年 6月 26 日,美國食品藥物管理局(FDA)授予 Clarius Health Corp 以人工智慧為基礎的手持式超音波設備的 510(k)許可。 Clarius OB AI 經過 30,000 多張胎兒超音波影像的訓練,可自動正確放置卡尺來計算胎兒生物特徵測量值,使用者可以透過 Clarius 應用程式將測量值傳輸到患者的電子健康記錄中。
妊娠相關併發症的日益普及是胎兒監測設備需求的主要驅動力。妊娠糖尿病、高血壓和早產等疾病變得越來越普遍,需要加強監測以確保母親和胎兒的健康和安全。由於這些併發症可能會導致嚴重的健康風險,因此醫療保健提供者越來越依賴胎兒監測系統來促進及時干預並有效管理高風險懷孕。技術的進步實現更準確、更有效率的監控解決方案,而這些設備的市場預計將會成長。孕婦對產前護理重要性的認識不斷提高,以及現代胎兒監測技術不斷評估胎兒和孕產婦健康的能力,推動了需求的激增。懷孕期間的問題,例如妊娠糖尿病和子癇前症,甚至在出生後幾十年也會增加死亡率。懷孕期間出現嚴重問題的女性過早死亡的風險較高。這種流行導致了全球胎兒監測市場的成長。
本報告調查了全球胎兒監護市場,包括市場概述以及依產品、攜帶性、方法、應用、最終用戶、地區趨勢和進入市場的公司概況。
Global fetal monitoring market is projected to witness a CAGR of 7.02% during the forecast period 2024-2031, growing from USD 4.54 billion in 2023 to USD 7.81 billion in 2031. Factors are driving the global fetal monitoring market such as increasing birth rates, prevalence of pregnancy related complications, and technological advancements.
Fetal monitoring devices are essential tools used to assess the health and well-being of a fetus during pregnancy. These devices include ultrasound systems, electronic fetal monitors, and fetal dopplers, which help healthcare providers to monitor fetal heart rates, movements, and maternal contractions. This growth is driven by several factors, including the rising incidence of preterm births and pregnancy-related complications, advancements in technology, and increasing awareness of prenatal care. However, challenges such as high costs, regulatory hurdles, and limited awareness among expectant mothers and healthcare providers may hinder market expansion. North America currently holds the largest market share, but Asia-Pacific is expected to exhibit the highest growth rate, influenced by improvements in healthcare infrastructure and rising demand for advanced monitoring solutions.
On 26th June 2024, the food and drug administration (FDA) granted 510(k) approval to Clarius Health Corp for its AI-based handheld ultrasound device. Clarius OB AI, has been trained on over 30,000 fetal ultrasound images, automates appropriate caliper placement for calculating fetal biometry measurements and allows users to add the measurements to patient electronic medical records via the Clarius app.
Increasing Prevalence of Pregnancy Related Complications
The increasing prevalence of pregnancy-related complications is significantly driving the demand for fetal monitoring devices. Conditions such as gestational diabetes, hypertension, and preterm labor have become more common, necessitating enhanced monitoring to ensure the health and safety of both the mother and fetus. As these complications can lead to serious health risks, healthcare providers are increasingly relying on fetal monitoring systems to facilitate timely interventions and manage high-risk pregnancies effectively. The market for these devices is projected to grow, with advancements in technology allowing for more accurate and efficient monitoring solutions. The surge in demand is fueled by rising awareness among expectant mothers about the importance of prenatal care and the capabilities of modern fetal monitoring technologies, which enable continuous assessment of fetal well-being and maternal health. Pregnancy problems, such as gestational diabetes or preeclampsia, may increase the chance of mortality even decades after delivery. Women who had serious problems during pregnancy have a higher risk of premature mortality. Such prevalence leads to growth of the global fetal monitoring market.
Technological Advancements to Drive Market Growth
Technological advancements in fetal monitoring are revolutionizing prenatal care, enhancing both the accuracy and convenience of monitoring fetal health. Innovations such as wearable devices, such as the abdominal patch developed by UC Irvine engineers in November 2022, allows expectant mothers to track fetal heart rates at home using a smartphone, promoting continuous monitoring without the need for trained technicians. The device utilizes an algorithm called Lullaby, which effectively isolates fetal electrocardiogram signals from maternal heartbeats, improving the clarity of data collected. Additionally, transabdominal fetal monitors are gaining traction, offering a non-invasive method that simplifies the monitoring process by using adhesive patches that do not require constant adjustments. These advancements improve the user experience and address challenges related to the global shortage of skilled healthcare professionals.
Portable Ultrasound Devices to Grow at a Fast Rate
Portable ultrasound devices are expected to see a significant increase in demand for fetal monitoring in the coming years due to several key factors. Handheld ultrasound systems are compact, lightweight, and easy for healthcare providers to use at the point-of-care, allowing for more frequent monitoring of fetal health. This is especially beneficial for high-risk pregnancies or in remote areas with limited access to traditional ultrasound machines. Technological advancements are enabling portable ultrasound devices to produce higher quality images comparable to cart-based systems. As the gap in functionality continues to decline, portable ultrasound will become an increasingly viable option for fetal monitoring. Artificial intelligence is being integrated with portable ultrasound to enhance diagnostic capabilities and guide treatment decisions, especially in emergency situations.
Konica Minolta Healthcare Americas, Inc. launched PocketPro H2, a wireless portable ultrasound device for general imaging in point-of-care applications, in July 2023. Konica Minolta Healthcare Americas Inc. partnered with Healcerion Co Ltd to commercialize the PocketPro H2 in the United States for urology and gynecology applications, bringing a new level of flexibility and affordability to ultrasound.
Hospitals to Dominate the Global Fetal Monitoring Market Share
Hospitals are equipped with advanced ultrasound technology and have specialists trained in interpreting fetal ultrasound images. They can provide comprehensive fetal monitoring throughout pregnancy, from early dating scans to detailed anatomy surveys and growth assessments. Hospitals have the capability to perform more specialized ultrasound exams such as fetal echocardiograms to evaluate the fetal heart. Additionally, hospitals are equipped to handle high-risk pregnancies that require closer monitoring, such as those with maternal conditions such as diabetes or preeclampsia, or fetal abnormalities detected in ultrasound. Portable ultrasound devices are increasingly being used in hospitals to provide point-of-care monitoring, allowing for more frequent checks on fetal well-being.
Future Market Scenario (2024-2031F)
Noninvasive fetal electrocardiography (ECG) and uterine contraction monitoring technologies are expected to bring novel metrics and potentially improved safety to obstetrics in coming years. These technologies filter ambient noise and focus on the fetal ECG waveform and uterine contraction patterns to provide more accurate monitoring. Fetal monitoring bands with innovative features like real-time data analysis, wireless connectivity, and portability are being introduced to make monitoring more convenient for providers and expectant mothers. These wearable devices allow for ambulatory monitoring outside the hospital setting.
Key Players Landscape and Outlook
The market witnessed some substantial market deals such as acquisitions, regulatory approvals, and product launches to expand the market share of key players. NeuroLogica Corp. launched the V6, their latest ultrasound system, in November 2023. The V6 provides full imaging capabilities in 2D, 3D, and color picture quality, with a focus on Women's Health and Urology. The V6 recently gained 510(k) clearance from the United States Food and Drug Administration for commercial usage, and it is intended to be cost-effective while meeting workflow and productivity requirements. A semi-automated tool based on deep learning that allows for one-click fetal growth measures, improving exam uniformity while minimizing keystrokes and allowing clinicians to focus more on patient care.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.